secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2024-07-22T23:59:59+00:00
Accession:  0001437749-24-023128
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences Executive Chairman outlines Phase 3 trial timelines and transparency pledge
--------------------------------------------------------------------------------

- First Phase 3 simufilam trial (804 patients) to read out by Dec 2024; second by June 2025.
- Rick Barry takes roles of Executive Chairman and principal executive officer until new CEO.
- Company commits to rigorous science and timely disclosure of material news, good or bad.
- Trial data held by Premier Research; biostatistics by Pentara – Cassava won't see results early.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924023128/0001437749-24-023128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924023128/sava20240721_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-023128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer